ExeVir Bio BV, a Belgian biotech has appointed a new chief scientific officer and head of operations as it advances its small-chain antibody therapeutics for infectious diseases. Viki Bockstal has become CSO and Caroline Sagaert is managing operations Dr Bocksal previously led preclinical development ExeVir. In her new role she will oversee the company’s expansion into new disease areas such as Dengue. She previously worked at Janssen Infectious Diseases & Vaccines. Ms Sagaert previously held leadership positions at GSK Plc and UCB SA.
Copyright 2023 Evernow Publishing Ltd